SCLEROCAR

A Phase 2a clinical trial evaluating the safety and efficacy of T cells expressing a chimeric antigen receptor targeting CD19 (CAR-T cells) in patients with systemic sclerosis (SSc) resistant to immunosuppressive drugs

Condition studied : Systemic sclerosis
Treatment : Anti-CD19 CAR-T cells
Inclusion criteria :

– Adult patients aged between 18 and 64
– Systemic sclerosis diagnosed within the last 5 years
– Moderate to severe skin involvement
– No response to three or more previous treatments for the condition

Exclusion criteria :

– Severe cardiac or pulmonary involvement
– Pulmonary arterial hypertension

Sponsor : Montpellier University Hospital
Principal Investigator : Pr. Christian Jorgensen
: NCT07493395 | Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy | ClinicalTrials.gov
Investigator
Pr. Christian Jorgensen
Director
Rechercher sur le site